604 related articles for article (PubMed ID: 17495880)
1. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
Kuypers DR; Naesens M; de Jonge H; Lerut E; Verbeke K; Vanrenterghem Y
Ther Drug Monit; 2010 Aug; 32(4):394-404. PubMed ID: 20526235
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients.
Kuypers DR; de Jonge H; Naesens M; Vanrenterghem Y
Pharmacogenet Genomics; 2008 Oct; 18(10):861-8. PubMed ID: 18704002
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
6. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
[TBL] [Abstract][Full Text] [Related]
7. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation.
Gervasini G; Garcia M; Macias RM; Cubero JJ; Caravaca F; Benitez J
Transpl Int; 2012 Apr; 25(4):471-80. PubMed ID: 22369694
[TBL] [Abstract][Full Text] [Related]
8. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
[TBL] [Abstract][Full Text] [Related]
9. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
[TBL] [Abstract][Full Text] [Related]
12. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
[TBL] [Abstract][Full Text] [Related]
13. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
[TBL] [Abstract][Full Text] [Related]
14. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
Vannaprasaht S; Reungjui S; Supanya D; Sirivongs D; Pongskul C; Avihingsanon Y; Tassaneeyakul W
Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.
Mourad M; Mourad G; Wallemacq P; Garrigue V; Van Bellingen C; Van Kerckhove V; De Meyer M; Malaise J; Eddour DC; Lison D; Squifflet JP; Haufroid V
Transplantation; 2005 Oct; 80(7):977-84. PubMed ID: 16249748
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
Díaz-Molina B; Tavira B; Lambert JL; Bernardo MJ; Alvarez V; Coto E
Transplant Proc; 2012 Nov; 44(9):2635-8. PubMed ID: 23146479
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
18. Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.
Vanhove T; Annaert P; Lambrechts D; Kuypers DRJ
Pharmacogenomics J; 2017 Dec; 17(6):556-562. PubMed ID: 27378609
[TBL] [Abstract][Full Text] [Related]
19. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.
Utecht KN; Hiles JJ; Kolesar J
Am J Health Syst Pharm; 2006 Dec; 63(23):2340-8. PubMed ID: 17106006
[TBL] [Abstract][Full Text] [Related]
20. Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant.
Alatorre-Moreno EV; Saldaña-Cruz AM; Pérez-Guerrero EE; Morán-Moguel MC; Contreras-Haro B; López-de La Mora DA; Dávalos-Rodríguez IP; Marín-Medina A; Rivera-Cameras A; Balderas-Peña LA; Gómez-Ramos JJ; Cortés-Sanabria L; Salazar-Páramo M
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
